- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
9
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
9 companies
Emergent BioSolutions
Market Cap: US$260.5m
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
EBS
US$5.08
7D
10.7%
1Y
-45.0%
Xeris Biopharma Holdings
Market Cap: US$1.6b
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$8.70
7D
1.2%
1Y
12.3%
Natera
Market Cap: US$47.9b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$332.03
7D
7.1%
1Y
100.5%
Teva Pharmaceutical Industries
Market Cap: US$43.5b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$37.34
7D
1.6%
1Y
102.3%
AbbVie
Market Cap: US$468.2b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$264.96
7D
6.2%
1Y
25.8%
Sotera Health
Market Cap: US$5.6b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$19.57
7D
3.6%
1Y
19.1%
Merck
Market Cap: US$376.4b
Operates as a healthcare company worldwide.
MRK
US$152.55
7D
12.3%
1Y
74.6%
Tempus AI
Market Cap: US$13.1b
Operates as a healthcare technology company in the United States.
TEM
US$72.69
7D
39.5%
1Y
-9.7%
Ligand Pharmaceuticals
Market Cap: US$5.7b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$286.29
7D
-2.8%
1Y
80.0%